<DOC>
	<DOCNO>NCT01155232</DOCNO>
	<brief_summary>Teriparatide ( PTH ) bone formation therapy approve treatment postmenopausal osteoporosis Canada . Osteoporosis currently diagnose use bone mineral density ( BMD ) scan , measure amount mineral ( calcium etc ) bone ( high amount mineral , low fracture risk ) . Although BMD link bone strength use measure fracture risk , give information bone structure ( call bone geometry ) also tell u great deal fracture risk . Clinical trial show teriparatide increase BMD lumbar spine total hip , BMD forearm may decrease 20 month therapy . However , bone biopsy pelvis do people take teriparatide show improvement bone geometry ( ie bone thickness increase trabecula ( small interconnecting rod bone ) , suggest change bone geometry wrist may occur well . Currently , new technology , high resolution pQCT ( HR-pQCT ) ass bone geometry without biopsy . Since bone strength affect BMD bone structure ( well material property ) , group interest examine change bone geometry radius tibia men woman osteoporosis receive 24 month teriparatide therapy . The investigator believe new approach measure bone strength help u good understand mechanisms therapeutic efficacy teriparatide . In addition , measure index bone strength material composition ( bone mineral content BMD ) structural property bone ( size shape , microarchitecture ) may provide data mechanism teriparatide treatment decrease fracture risk . In end , data benefit improve patient care allow u show patient provider whether BMD increase , decrease stay , change bone geometric structure teriparatide therapy increase bone strength .</brief_summary>
	<brief_title>Effects Teriparatide ( PTH ) Bone Men Women With Osteoporosis</brief_title>
	<detailed_description>Teriparatide ( PTH ) bone formation therapy approve treatment postmenopausal osteoporosis Canada . Randomized control trial show teriparatide increase bone mineral density ( BMD ) lumbar spine total hip , BMD forearm may decrease 20 month therapy . It believe decline BMD distal radius observe teriparatide therapy may indicative decrease bone strength , may result increase width radius . Teriparatide work induce new periosteal bone apposition , result improve bone geometry increase bone strength may reflect BMD measurement . However , publish data bone geometric change radius either bone biopsy HR-pQCT patient receive teriparatide therapy . It intention fill gap knowledge regard teriparatide affect BMD bone structure radius tibia men woman osteoporosis . The main objective study determine effect 24 month teriparatide therapy cortical thickness , trabecular thickness , trabecular number , trabecular separation BV/TV , measure HR-pQCT ( XtremeCT , Scanco Medical , Switzerland ) radius tibia men woman osteoporosis . The primary outcome cortical thickness ; measure secondary outcome . The secondary objective determine effect 24 month teriparatide therapy moment inertia , connectivity index , bone strength , measure HR-pQCT calculate use finite element model analysis radius tibia men woman osteoporosis . This open label study cohort 100 men woman take teriparatide 24 month . As observational study , study medication supply study participant . Recruitment subject referral specialty clinic participate investigator . Participants undergo two ( 2 ) procedure five ( 7 ) separate occasion ( baseline , 6 , 12 , 18 24 month , post therapy 36 48 month ) . The procedure HR-pQCT DXA . In addition procedure , subject ask complete blood test part standard clinical practice . Blood do baseline , 1 month 18 month . A follow phone call also make patient 1 month discus update patient 's health status ensure patient complete 1 month blood test . Understanding effect teriparatide bone geometry BMD enable u good understand effect teriparatide bone strength radius tibia , bone strength general , even BMD stay decrease course treatment .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>History fragility fracture OR High risk fracture OR Very low BMD ( Tscore â‰¤ 2.5 ) OR Failed intolerant bisphosphonates Baseline serum level calcium , urate , ALP , PTH , creatinine 25 hydroxyvitamin D [ 25 ( OH ) D ] must within acceptable normal limit Ability obtain teriparatide ( supply study sponsor ) History skeletal irradiation Those increase risk osteosarcoma Diagnosis Paget 's disease History primary hyperparathyroidism Significant renal impairment Vitamin D deficiency On steroid cause secondary osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>Forteo</keyword>
	<keyword>Parathyroid hormone</keyword>
	<keyword>HR-pQCT</keyword>
</DOC>